Multihance (Gadobenate Dimeglumine)

Gadobenate dimeglumine, the active ingredient in Multihance, is a gadolinium-based contrast agent presented as a 0.5 mmol/mL solution for injection for intravenous use. It enhances magnetic resonance imaging of specific organs and vascular structures in adult patients.

GNH USA supplies Multihance as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Multihance is used in magnetic resonance imaging procedures to improve visualization of the central nervous system, liver, vascular system, and cardiac structures.

- Central nervous system MRI: provides enhanced signal intensity for better lesion detection and anatomical detail. - Liver MRI: improves lesion conspicuity and characterization of hepatic lesions. - Magnetic resonance angiography (MRA): increases vascular contrast for clearer depiction of arteries and veins. - Cardiac MRI: enhances myocardial and blood‑pool visualization for functional and perfusion assessment.

Adverse reactions may occur following intravenous administration of gadolinium‑based contrast agents.

Common Side Effects: - Nausea: mild to moderate feeling of stomach upset. - Headache: transient discomfort after injection. - Injection site discomfort: pain or burning sensation at the cannula site. - Warmth or flushing: sensation of heat spreading through the body. - Metallic taste: brief metallic sensation in the mouth. - Dizziness: light‑headed feeling that usually resolves quickly.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical intervention. - Nephrogenic systemic fibrosis (NSF): rare fibrotic disorder in patients with severe renal impairment. - Severe hypotension: marked drop in blood pressure shortly after injection. - Cardiac arrest: extremely rare but life‑threatening event. - Acute kidney injury: sudden decline in renal function, especially in at‑risk patients. - Pulmonary edema: accumulation of fluid in the lungs, presenting with shortness of breath.

Prior to using Multihance, clinicians should assess patient-specific risk factors and follow handling guidelines. - Renal function assessment: evaluate kidney function (eGFR) before administration. - Pregnancy: use only if clearly needed, as safety data are limited. - Breastfeeding: consider potential exposure to the infant and weigh benefits versus risks. - History of allergic reactions: review prior contrast media reactions and be prepared for emergency management. - Concurrent nephrotoxic drugs: monitor renal status when used with agents that may impair kidney function. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Gadobenate dimeglumine may interact with other agents that affect renal function or increase gadolinium load.

Major Interactions (Avoid): - Severe renal impairment (eGFR <30 mL/min/1.73 m²): heightened risk of nephrogenic systemic fibrosis; avoid use. - Concurrent administration of other gadolinium‑based agents: cumulative gadolinium exposure may increase toxicity.

Moderate Interactions (Monitor Closely): - Loop diuretics: may alter renal clearance, requiring closer monitoring of kidney function. - Nephrotoxic antibiotics (e.g., aminoglycosides, vancomycin): increase risk of renal injury; assess renal parameters. - ACE inhibitors or ARBs: may affect renal perfusion; monitor for changes in renal function. - High‑dose corticosteroids: potential for altered fluid balance; observe for adverse effects.